Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E-VIRTUE: Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors
NCT06041503Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Jan 2026
- Primary completion
- Oct 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of enfortumab vedotin in Adenocarcinoma of the urinary tract, squamous cell carcinoma of the urinary tract (UTSCC), Testicular Germ Cell Tumor (TGCT), sponsored by National Cancer Institute. Started Jan 2026; status: recruiting.
02
Drugs
enfortumab vedotin
03
Conditions
Adenocarcinoma of the urinary tractsquamous cell carcinoma of the urinary tract (UTSCC)Testicular Germ Cell Tumor (TGCT)
Beyond the preview
Go deeper on NCT06041503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06041503.